# Protalix BioTherapeutics, Inc.: financial statements, quarterly

PLX · NYSE · CIK 1006281 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/plx.md) · [Financials](/companies/plx/financials.md) · [Filings](/companies/plx/filings.md) · [Insiders](/companies/plx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/plx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [10.3](/filings/0001558370-24-015612.md) | [10.5 d](/filings/0001104659-26-029858.md) | [3.7](/filings/0001558370-25-007063.md) | [13.5](/filings/0001558370-25-011471.md) | [18.0](/filings/0001104659-25-110824.md) | [18.2 d](/filings/0001104659-26-029858.md) | [10.1](/filings/0001104659-26-059756.md) | [15.7](/filings/0001104659-26-094444.md) | [17.9](/filings/0001104659-25-110824.md) | [9.1 d](/filings/0001104659-26-029858.md) | [33.8](/filings/0001104659-26-059756.md) | [19.9](/filings/0001104659-26-094444.md) |
| Cost of revenue | $m | [4.9](/filings/0001558370-24-015612.md) | [8.9 d](/filings/0001104659-26-029858.md) | [2.6](/filings/0001558370-25-007063.md) | [9.5](/filings/0001558370-25-011471.md) | [8.4](/filings/0001104659-25-110824.md) | [3.9 d](/filings/0001104659-26-029858.md) | [8.2](/filings/0001104659-26-059756.md) | [5.9](/filings/0001104659-26-094444.md) | [8.3](/filings/0001104659-25-110824.md) | [4.6 d](/filings/0001104659-26-029858.md) | [4.1](/filings/0001104659-26-059756.md) | [7.8](/filings/0001104659-26-094444.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [3.7](/filings/0001558370-24-015612.md) | [3.1 d](/filings/0001104659-26-029858.md) | [2.9](/filings/0001558370-25-007063.md) | [3.0](/filings/0001558370-25-011471.md) | [3.0](/filings/0001104659-25-110824.md) | [4.1 d](/filings/0001104659-26-029858.md) | [3.5](/filings/0001104659-26-059756.md) | [6.0](/filings/0001104659-26-094444.md) | [4.5](/filings/0001104659-25-110824.md) | [5.6 d](/filings/0001104659-26-029858.md) | [5.4](/filings/0001104659-26-059756.md) | [4.4](/filings/0001104659-26-094444.md) |
| Selling, general and administrative | $m | [3.7](/filings/0001558370-24-015612.md) | [4.1 d](/filings/0001104659-26-029858.md) | [3.1](/filings/0001558370-25-007063.md) | [3.5](/filings/0001558370-25-011471.md) | [2.6](/filings/0001104659-25-110824.md) | [3.0 d](/filings/0001104659-26-029858.md) | [2.6](/filings/0001104659-26-059756.md) | [2.6](/filings/0001104659-26-094444.md) | [2.9](/filings/0001104659-25-110824.md) | [3.5 d](/filings/0001104659-26-029858.md) | [3.1](/filings/0001104659-26-059756.md) | [3.1](/filings/0001104659-26-094444.md) |
| Operating income | $m | [(1.9)](/filings/0001558370-24-015612.md) | [(5.6) d](/filings/0001104659-26-029858.md) | [(4.9)](/filings/0001558370-25-007063.md) | [(2.4)](/filings/0001558370-25-011471.md) | [4.0](/filings/0001104659-25-110824.md) | [7.2 d](/filings/0001104659-26-029858.md) | [(4.1)](/filings/0001104659-26-059756.md) | [1.2](/filings/0001104659-26-094444.md) | [2.1](/filings/0001104659-25-110824.md) | [(4.7) d](/filings/0001104659-26-029858.md) | [21.1](/filings/0001104659-26-059756.md) | [4.7](/filings/0001104659-26-094444.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.1](/filings/0001558370-24-015612.md) | [(0.4) d](/filings/0001104659-26-029858.md) | [(0.1)](/filings/0001558370-25-007063.md) | [(0.1)](/filings/0001558370-25-011471.md) | [0.6](/filings/0001104659-25-110824.md) | [0.8 d](/filings/0001104659-26-029858.md) | [(0.1)](/filings/0001104659-26-059756.md) | [0.5](/filings/0001104659-26-094444.md) | [(0.1)](/filings/0001104659-25-110824.md) | [0.7 d](/filings/0001104659-26-029858.md) | [2.8](/filings/0001104659-26-059756.md) | [1.1](/filings/0001104659-26-094444.md) |
| Net income | $m | [(1.9)](/filings/0001558370-24-015612.md) | [(6.0) d](/filings/0001104659-26-029858.md) | [(4.6)](/filings/0001558370-25-007063.md) | [(2.2)](/filings/0001558370-25-011471.md) | [3.2](/filings/0001104659-25-110824.md) | [6.5 d](/filings/0001104659-26-029858.md) | [(3.6)](/filings/0001104659-26-059756.md) | [0.2](/filings/0001104659-26-094444.md) | [2.4](/filings/0001104659-25-110824.md) | [(5.5) d](/filings/0001104659-26-029858.md) | [18.3](/filings/0001104659-26-059756.md) | [3.8](/filings/0001104659-26-094444.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0001558370-24-015612.md) | not reported | [(0.06)](/filings/0001558370-25-007063.md) | [(0.03)](/filings/0001558370-25-011471.md) | [0.03](/filings/0001104659-25-110824.md) | not reported | [(0.05)](/filings/0001104659-26-059756.md) | [0.00](/filings/0001104659-26-094444.md) | [0.03](/filings/0001104659-25-110824.md) | not reported | [0.22](/filings/0001104659-26-059756.md) | [0.05](/filings/0001104659-26-094444.md) |
| Basic EPS | $ per share | [(0.03)](/filings/0001558370-24-015612.md) | not reported | [(0.06)](/filings/0001558370-25-007063.md) | [(0.03)](/filings/0001558370-25-011471.md) | [0.04](/filings/0001104659-25-110824.md) | not reported | [(0.05)](/filings/0001104659-26-059756.md) | [0.00](/filings/0001104659-26-094444.md) | [0.03](/filings/0001104659-25-110824.md) | not reported | [0.23](/filings/0001104659-26-059756.md) | [0.05](/filings/0001104659-26-094444.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [20.4](/filings/0001558370-23-017664.md) | [23.6](/filings/0001558370-25-003039.md) | [27.2](/filings/0001558370-24-007695.md) | [23.4](/filings/0001558370-24-012134.md) | [27.4](/filings/0001558370-24-015612.md) | [19.8](/filings/0001104659-26-029858.md) | [19.5](/filings/0001558370-25-007063.md) | [17.9](/filings/0001558370-25-011471.md) | [13.6](/filings/0001104659-25-110824.md) | [14.7](/filings/0001104659-26-094444.md) | [41.0](/filings/0001104659-26-059756.md) | [27.4](/filings/0001104659-26-094444.md) |
| Current assets | $m | [72.6](/filings/0001558370-23-017664.md) | [69.9](/filings/0001558370-25-003039.md) | [75.4](/filings/0001558370-24-007695.md) | [77.4](/filings/0001558370-24-012134.md) | [47.9](/filings/0001558370-24-015612.md) | [60.1](/filings/0001104659-26-029858.md) | [60.5](/filings/0001558370-25-007063.md) | [65.5](/filings/0001558370-25-011471.md) | [66.5](/filings/0001104659-25-110824.md) | [66.7](/filings/0001104659-26-094444.md) | [86.4](/filings/0001104659-26-059756.md) | [92.2](/filings/0001104659-26-094444.md) |
| Total assets | $m | [87.6](/filings/0001558370-23-017664.md) | [84.4](/filings/0001558370-25-003039.md) | [89.8](/filings/0001558370-24-007695.md) | [91.5](/filings/0001558370-24-012134.md) | [61.6](/filings/0001558370-24-015612.md) | [73.4](/filings/0001104659-26-029858.md) | [73.9](/filings/0001558370-25-007063.md) | [78.5](/filings/0001558370-25-011471.md) | [82.3](/filings/0001104659-25-110824.md) | [82.3](/filings/0001104659-26-094444.md) | [102](/filings/0001104659-26-059756.md) | [110](/filings/0001104659-26-094444.md) |
| Current liabilities | $m | [43.4](/filings/0001558370-23-017664.md) | [45.5](/filings/0001558370-25-003039.md) | [54.8](/filings/0001558370-24-007695.md) | [58.0](/filings/0001558370-24-012134.md) | [24.2](/filings/0001558370-24-015612.md) | [25.6](/filings/0001104659-26-029858.md) | [24.3](/filings/0001558370-25-007063.md) | [24.1](/filings/0001558370-25-011471.md) | [21.9](/filings/0001104659-25-110824.md) | [26.5](/filings/0001104659-26-094444.md) | [27.4](/filings/0001104659-26-059756.md) | [31.4](/filings/0001104659-26-094444.md) |
| Total liabilities | $m | [49.3](/filings/0001558370-23-017664.md) | [50.9](/filings/0001558370-25-003039.md) | [60.0](/filings/0001558370-24-007695.md) | [63.0](/filings/0001558370-24-012134.md) | [29.1](/filings/0001558370-24-015612.md) | [30.2](/filings/0001104659-26-029858.md) | [28.7](/filings/0001558370-25-007063.md) | [28.6](/filings/0001558370-25-011471.md) | [29.4](/filings/0001104659-25-110824.md) | [34.1](/filings/0001104659-26-094444.md) | [35.1](/filings/0001104659-26-059756.md) | [38.9](/filings/0001104659-26-094444.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [38.2](/filings/0001558370-24-015612.md) | [33.6](/filings/0001104659-26-029858.md) | [29.8](/filings/0001558370-25-011471.md) | [28.6](/filings/0001104659-25-110824.md) | [32.4](/filings/0001104659-25-110824.md) | [43.2](/filings/0001104659-26-094444.md) | [45.2](/filings/0001104659-26-094444.md) | [49.9](/filings/0001104659-26-094444.md) | [52.9](/filings/0001104659-25-110824.md) | [48.2](/filings/0001104659-26-094444.md) | [67.2](/filings/0001104659-26-094444.md) | [71.4](/filings/0001104659-26-094444.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.9) d](/filings/0001558370-24-015612.md) | [3.6 d](/filings/0001104659-26-029858.md) | [4.2](/filings/0001558370-25-007063.md) | [(3.6) d](/filings/0001558370-25-011471.md) | [4.1 d](/filings/0001104659-25-110824.md) | [4.0 d](/filings/0001104659-26-029858.md) | [(5.1)](/filings/0001104659-26-059756.md) | [(5.2) d](/filings/0001104659-26-094444.md) | [(3.7) d](/filings/0001104659-25-110824.md) | [2.0 d](/filings/0001104659-26-029858.md) | [22.0](/filings/0001104659-26-059756.md) | [(10.4) d](/filings/0001104659-26-094444.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001558370-24-015612.md) | [0.3 d](/filings/0001104659-26-029858.md) | [0.6](/filings/0001558370-25-007063.md) | [0.2 d](/filings/0001558370-25-011471.md) | [0.1 d](/filings/0001104659-25-110824.md) | [0.4 d](/filings/0001104659-26-029858.md) | [0.3](/filings/0001104659-26-059756.md) | [0.4 d](/filings/0001104659-26-094444.md) | [0.5 d](/filings/0001104659-25-110824.md) | [0.4 d](/filings/0001104659-26-029858.md) | [0.8](/filings/0001104659-26-059756.md) | [0.6 d](/filings/0001104659-26-094444.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [49.5](/filings/0001558370-23-017664.md) | [57.5](/filings/0001558370-24-007695.md) | [83.2](/filings/0001558370-24-012134.md) | [83.8](/filings/0001558370-24-015612.md) | [73.0](/filings/0001558370-25-007063.md) | [73.3](/filings/0001558370-25-011471.md) | [81.2](/filings/0001104659-25-110824.md) | [76.6](/filings/0001104659-26-059756.md) | [81.3](/filings/0001104659-26-094444.md) | [80.8](/filings/0001104659-25-110824.md) | [83.0](/filings/0001104659-26-059756.md) | [82.6](/filings/0001104659-26-094444.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 80,571,642 at 2026-08-01, from the cover of the [10-Q filed 2026-08-12](/filings/0001104659-26-094444.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.